HS
ITCI

Horan Securities’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Horan Securities’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7
Closed -$370 – 835
2022
Q4 		$370 Buy
+7
New +$351 ﹤0.01% 731

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Horan Securities's ITCI Position: Q1 2023 in Review

Horan Securities sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2023, closing a stake of 7 shares — an estimated $370 sold.

Horan Securities first reported a position in ITCI in Q4 2022 and held it in 1 quarter. The position peaked at $370 in Q4 2022. 274 funds tracked by Wall St. Rank hold ITCI as of Q1 2023.

  • Horan Securities reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2023 after selling out during the quarter.
  • Horan Securities sold 7 Intra-Cellular Therapies Inc. shares in Q1 2023, an estimated $370.
  • Horan Securities first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 1 quarter.
  • Horan Securities's Intra-Cellular Therapies Inc. position peaked at $370 in Q4 2022.
  • 274 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2023.

Based on Horan Securities's 13F filing for Q1 2023, filed 18 Apr 2023.